Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls.
暂无分享，去创建一个
A. Iafrate | A. Shaw | B. Yeap | Gregory Riely | S. Ou | R. Salgia | M. Varella‐Garcia | G. Shapiro | D. Costa | K. Wilner | B. Solomon | R. Maki | D. Camidge | E. Kwak | J. Clark | M. Butaney | P. Selaru | K. Kulig | Y. Tang | Y. Bang | M. Varella-Garcia